{
    "nctId": "NCT00283608",
    "briefTitle": "Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer",
    "officialTitle": "Pharmacogenetics of Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1000,
    "primaryOutcomeMeasure": "Association of single nucleotide polymorphisms with specific quantitative traits (i.e., hormone levels, breast density, and bone mineral density)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer\n\n  * Stage I, II, or III disease\n  * Resected disease\n* Planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day OR Mayo Clinic Cancer Center Rochester patient who will be enrolled on or has been enrolled on CAN-NCIC-MA27 and has not started taking the study medication (anastrozole or exemestane)\n* Hormone receptor status:\n\n  * Estrogen receptor-positive and/or progesterone receptor-positive primary tumor\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal\n* Able to complete questionnaires alone or with assistance\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 6 months since prior endocrine therapy, except tamoxifen\n* No other prior aromatase inhibitors (e.g., letrozole or exemestane)\n* No prior ovarian function suppression with surgery or radiotherapy, ovarian ablation, or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}